## Paul Andrew VanderLaan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5857892/publications.pdf

Version: 2024-02-01

139 papers 4,778 citations

34 h-index 102304 66 g-index

141 all docs

141 docs citations

141 times ranked

6772 citing authors

#	Article	IF	Citations
1	Site Specificity of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 12-22.	1.1	509
2	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications, 2015, 6, 6377.	5.8	498
3	Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers. Lung Cancer, 2015, 88, 108-111.	0.9	369
4	Clinical Outcome for Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations. American Journal of Clinical Pathology, 2011, 135, 770-775.	0.4	197
5	Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer, 2017, 106, 17-21.	0.9	149
6	Mammary analogue secretory carcinoma: Update on a new diagnosis of salivary gland malignancy. Laryngoscope, 2014, 124, 188-195.	1.1	147
7	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer, 2014, 84, 39-44.	0.9	135
8	The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio. Cancer Cytopathology, 2012, 120, 111-116.	1.4	119
9	Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, 878-883.	0.5	109
10	Usefulness of Diagnostic Qualifiers for Thyroid Fine-Needle Aspirations With Atypia of Undetermined Significance. American Journal of Clinical Pathology, 2011, 136, 572-577.	0.4	102
11	Thematic review series: The Immune System and Atherogenesis. The unusual suspects:an overview ofthe minor leukocyte populations in atherosclerosis. Journal of Lipid Research, 2005, 46, 829-838.	2.0	89
12	Endobronchial ultrasoundâ€guided transbronchial needle aspiration (EBUSâ€₹BNA): An overview and update for the cytopathologist. Cancer Cytopathology, 2014, 122, 561-576.	1.4	86
13	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1037-1042.	0.5	83
14	Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size. Journal of Thoracic Oncology, 2017, 12, 1288-1298.	0.5	75
15	Characterization of the Natural Killer T-Cell Response in an Adoptive Transfer Model of Atherosclerosis. American Journal of Pathology, 2007, 170, 1100-1107.	1.9	71
16	Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1438-1444.	0.5	71
17	Fineâ€needle aspiration and core needle biopsy: An update on 2 common minimally invasive tissue sampling modalities. Cancer Cytopathology, 2016, 124, 862-870.	1.4	71
18	Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer, 2015, 90, 369-374.	0.9	70

#	Article	IF	Citations
19	VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice. Journal of Lipid Research, 2009, 50, 376-385. Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies:	2.0	69
20	Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology. Archives of Pathology and Laboratory	1,2	65
21	Medicine, 2020, 144, 933-958.  Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5963-5976.	3.2	63
22	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. Journal of Thoracic Oncology, 2019, 14, 1995-2002.	0.5	58
23	The Frequency of â€ <sup>~</sup> Atypia of Undetermined Significance' Interpretations for Thyroid Fine-Needle Aspirations Is Negatively Correlated with Histologically Proven Malignant Outcomes. Acta Cytologica, 2011, 55, 512-517.	0.7	57
24	Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for reporting thyroid cytopathology. Cancer Cytopathology, 2012, 120, 245-253.	1.4	56
25	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. Journal of the American Society of Cytopathology, 2018, 7, 133-141.	0.2	56
26	Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology. Diagnostic Cytopathology, 2016, 44, 1000-1009.	0.5	55
27	EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review. Clinical Lung Cancer, 2016, 17, 483-492.	1.1	52
28	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer, 2013, 82, 31-37.	0.9	48
29	Global impact of the COVIDâ€19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathology, 2020, 128, 885-894.	1.4	47
30	Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer, 2018, 116, 90-95.	0.9	46
31	CT Manifestations of Tumor Spread Through Airspaces in Pulmonary Adenocarcinomas Presenting as Subsolid Nodules. Journal of Thoracic Imaging, 2018, 33, 402-408.	0.8	43
32	6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met. Biochemical and Biophysical Research Communications, 2013, 439, 247-251.	1.0	42
33	Osseous and chondromatous metaplasia in calcific aortic valve stenosis. Cardiovascular Pathology, 2016, 25, 18-24.	0.7	37
34	Atypia of Undetermined Significance and Nondiagnostic Rates in The Bethesda System for Reporting Thyroid Cytopathology Are Inversely Related. American Journal of Clinical Pathology, 2012, 137, 462-465.	0.4	35
35	Natural killer T cells in lipoprotein metabolism and atherosclerosis. Thrombosis and Haemostasis, 2011, 106, 814-819.	1.8	33
36	Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1164-1179.	2.5	32

#	Article	IF	CITATIONS
37	Molecular Testing Turnaround Time for Non–Small Cell Lung Cancer in Routine ClinicalÂPractice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis. Clinical Lung Cancer, 2017, 18, e349-e356.	1.1	31
38	Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?. , 2020, 8, e000697.		31
39	De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer, 2015, 88, 70-73.	0.9	30
40	Molecular markers: Implications for cytopathology and specimen collection. Cancer Cytopathology, 2015, 123, 454-460.	1.4	30
41	Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer, 2019, 125, 4164-4171.	2.0	30
42	Results from the 2019 American Society of Cytopathology survey on rapid on-site evaluationâ€"Part 1: objective practice patterns. Journal of the American Society of Cytopathology, 2019, 8, 333-341.	0.2	30
43	The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non–Small-Cell Lung Cancer: A Mini-Review. Clinical Lung Cancer, 2015, 16, 334-339.e1.	1.1	28
44	Software-based risk stratification of pulmonary adenocarcinomas manifesting as pure ground glass nodules on computed tomography. European Radiology, 2018, 28, 235-242.	2.3	28
45	Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules â‰30 mm on CT. Academic Radiology, 2017, 24, 851-859.	1.3	26
46	EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports, 2020, 1, 100051.	0.6	26
47	Experience with targeted next generation sequencing for the care of lung cancer: Insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treatment Communications, 2015, 4, 174-181.	0.4	24
48	Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. Translational Lung Cancer Research, 2015, 4, 392-403.	1.3	24
49	Esophagitis: A Novel Adverse Event of Crizotinib in a Patient with ALK-Positive Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, e23-e24.	0.5	23
50	Implementation of the Paris System for Reporting Urinary Cytology results in lower atypical diagnostic rates. Journal of the American Society of Cytopathology, 2017, 6, 205-210.	0.2	22
51	Repeatedly Nondiagnostic Thyroid Fine-Needle Aspirations Do Not Modify Malignancy Risk. Acta Cytologica, 2011, 55, 539-543.	0.7	20
52	Measurement Bias of Gross Pathologic Compared With Radiologic Tumor Size of Resected Lung Adenocarcinomas. American Journal of Clinical Pathology, 2017, 147, 641-648.	0.4	20
53	Measuring and assuring quality performance in cytology: A toolkit. Cancer Cytopathology, 2017, 125, 502-507.	1.4	20
54	Preâ€analytic error: A significant patient safety risk. Cancer Cytopathology, 2018, 126, 738-744.	1.4	19

#	Article	IF	Citations
55	Current and future trends in non–small cell lung cancer biomarker testing: The American experience. Cancer Cytopathology, 2020, 128, 629-636.	1.4	18
56	Visceral Pleural Invasion in Pulmonary Adenocarcinoma: Differences in CT Patterns between Solid and Subsolid Cancers. Radiology: Cardiothoracic Imaging, 2019, 1, e190071.	0.9	17
57	De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naÃ <sup>-</sup> ve ALK rearranged lung cancers. Lung Cancer, 2016, 99, 17-22.	0.9	16
58	Molecular testing results as a quality metric for evaluating cytopathologists' utilization of the atypia of undetermined significance category for thyroid nodule fine-needle aspirations. Journal of the American Society of Cytopathology, 2022, 11, 67-73.	0.2	16
59	Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. Journal of Thoracic Oncology, 2017, 12, e175-e177.	0.5	15
60	Preoperative cytologic interpretation of noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a 1-year multi-institutional experience. Journal of the American Society of Cytopathology, 2018, 7, 79-85.	0.2	15
61	Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with <i>EGFR</i> G719A and Other Uncommon <i>EGFR</i> Mutations. Oncologist, 2021, 26, 281-287.	1.9	15
62	Macrophage Migration Inhibitory Factor as a Novel Biomarker of Portopulmonary Hypertension. Pulmonary Circulation, 2016, 6, 498-507.	0.8	15
63	COVIDâ€19 pandemic impact on cytopathology practice in the postâ€lockdown period: An international, multicenter study. Cancer Cytopathology, 2022, 130, 344-351.	1.4	15
64	The Growth Rate of Subsolid Lung Adenocarcinoma Nodules at Chest CT. Radiology, 2020, 297, 189-198.	3.6	14
65	Molecular Testing Turnaround Time in Non–Small-Cell Lung Cancer: Monitoring a Moving Target. Clinical Lung Cancer, 2018, 19, e589-e590.	1.1	13
66	Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non†small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e379-e389.	1.1	13
67	The rapidly evolving landscape of biomarker testing in non–small cell lung cancer. Cancer Cytopathology, 2021, 129, 179-181.	1.4	13
68	"Rounding―the Size of Pulmonary Nodules. Academic Radiology, 2017, 24, 1422-1427.	1.3	12
69	Recovery of giant-cell myocarditis using combined cytolytic immunosuppression and mechanical circulatory support. Journal of Heart and Lung Transplantation, 2014, 33, 769-771.	0.3	11
70	Results from the 2019 American Society ofÂCytopathology survey on rapid onsite evaluation (ROSE)–part 2: subjective views among the cytopathology community. Journal of the American Society of Cytopathology, 2020, 9, 570-578.	0.2	11
71	The Immune System and Murine Atherosclerosis. Current Drug Targets, 2007, 8, 1297-1306.	1.0	10
72	Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clinical Lung Cancer, 2015, 16, e105-e109.	1.1	10

#	Article	IF	CITATIONS
73	Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. Cancer Treatment and Research Communications, 2018, 15, 17-20.	0.7	10
74	Preoperative bronchial cytology for the assessment of tumor spread through air spaces in lung adenocarcinoma resection specimens. Cancer Cytopathology, 2020, 128, 278-286.	1.4	10
<b>7</b> 5	Combined molecular and histologic end points inform cancer risk estimates for thyroid nodules classified as atypia of undetermined significance. Cancer Cytopathology, 2021, 129, 947-955.	1.4	10
76	Cytologic rapid on-site evaluation of transthoracic computed tomography–guided lung needle biopsies: who should perform ROSE? A cross-institutional analysis of procedural and diagnostic outcomes. Journal of the American Society of Cytopathology, 2015, 4, 160-169.	0.2	9
77	De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. Lung Cancer, 2017, 114, 108-110.	0.9	9
78	Pathologic T Descriptor of Nonmucinous Lung Adenocarcinomas Now Based on Invasive Tumor Size. American Journal of Clinical Pathology, 2018, 150, 499-506.	0.4	9
79	Growth Assessment of Pulmonary Adenocarcinomas Manifesting as Subsolid Nodules on CT: Comparison of Diameter-Based and Volume Measurements. Academic Radiology, 2020, 27, 1385-1393.	1.3	9
80	Activity of Brigatinib in the Setting of AlectinibÂResistance Mediated by ALK I1171S inÂALK-Rearranged Lung Cancer. Journal of Thoracic Oncology, 2019, 14, e1-e3.	0.5	8
81	Rapidly fatal advanced EGFR -mutated lung cancers and the need for rapid tumor genotyping in clinical practice. Cancer Treatment and Research Communications, 2016, 9, 41-43.	0.7	7
82	Comparison of plasma-thrombin, HistoGel, and CellGel cell block preparation methods with paired ThinPrep slides in the setting of mediastinal granulomatous disease. Journal of the American Society of Cytopathology, 2019, 8, 52-60.	0.2	7
83	Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2018, 36, 9069-9069.	0.8	7
84	Pulmonary Sclerosing Pneumocytoma. Journal of Bronchology and Interventional Pulmonology, 2018, 25, e54-e56.	0.8	6
85	Histopathological Demonstration of Subacute Endothelialization Following Aneurysm Retreatment with the Pipeline Embolization Device. World Neurosurgery, 2018, 118, 156-160.	0.7	6
86	Lymphangioleiomyomatosis. New England Journal of Medicine, 2018, 378, 2224-2224.	13.9	6
87	CT Manifestations of Tumor Spread through Air Spaces in Lung Adenocarcinoma: Different Pathways toward Common Perspectives. Radiology, 2019, 290, 271-272.	3.6	6
88	CCAAT/Enhancer Binding Protein $\hat{l}^2$ Is Dispensable for Development of Lung Adenocarcinoma. PLoS ONE, 2015, 10, e0120647.	1.1	6
89	Vascular remodeling of the small pulmonary arteries and measures of vascular pruning on computed tomography. Pulmonary Circulation, 2021, 11, 1-9.	0.8	6
90	Practical Approach to the Evaluation of Prosthetic Mechanical and Tissue Replacement Heart Valves. Surgical Pathology Clinics, 2012, 5, 353-369.	0.7	5

#	Article	IF	Citations
91	Pill Aspiration Presenting as an Endobronchial Tumor. Journal of Bronchology and Interventional Pulmonology, 2014, 21, 162-165.	0.8	5
92	Invariant Natural Killer T-Cells and Total CD1d Restricted Cells Differentially Influence Lipid Metabolism and Atherosclerosis in Low Density Receptor Deficient Mice. International Journal of Molecular Sciences, 2019, 20, 4566.	1.8	5
93	Non–small cell lung cancer predictive biomarker testing via immunocytochemistry: Ways of future past?. Cancer Cytopathology, 2019, 127, 278-280.	1.4	5
94	Assessing invasiveness of subsolid lung adenocarcinomas with combined attenuation and geometric feature models. Scientific Reports, 2020, 10, 14585.	1.6	5
95	Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies Guideline from the College of American Pathologists (CAP): implications for the cytology community. Journal of the American Society of Cytopathology, 2020, 9, 286-290.	0.2	5
96	A Case of Hypercalcemia Secondary to Hot Tub Lung. Chest, 2014, 146, e186-e189.	0.4	4
97	Updates in Lung Cancer Cytopathology. Surgical Pathology Clinics, 2018, 11, 515-522.	0.7	4
98	Yield of biliary stent cytology: Is it time to think lean?. Endoscopy International Open, 2019, 07, E545-E550.	0.9	4
99	Thermoablative Techniques for Excessive Central Airway Collapse. Journal of Bronchology and Interventional Pulmonology, 2020, 27, 195-199.	0.8	4
100	The natural course of incidentally detected, small, subsolid lung nodules—is follow-up needed beyond current guideline recommendations?. Translational Lung Cancer Research, 2019, 8, S412-S417.	1.3	3
101	CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in Ldlrâ <sup>-</sup> '/â <sup>-</sup> ' Mice. Antibodies, 2020, 9, 30.	1.2	3
102	EGFR-A763_Y764insFQEA: A unique exon 20 insertion mutation that displays sensitivity to all classes of approved lung cancer EGFR tyrosine kinase inhibitors Journal of Clinical Oncology, 2019, 37, e20593-e20593.	0.8	3
103	Percutaneous Lung Biopsy: Point—Fine-Needle Aspiration First. American Journal of Roentgenology, 2022, 218, 794-795.	1.0	3
104	All in for patient safety: a team approach to quality improvement in our laboratories. Journal of the American Society of Cytopathology, 2022, 11, 87-93.	0.2	3
105	A microthymoma and no germinal centre in myasthenia gravis. European Journal of Cardio-thoracic Surgery, 2013, 44, 1146-1147.	0.6	2
106	EBUS-TBNA of Pulmonary Artery Clot. Journal of Bronchology and Interventional Pulmonology, 2014, 21, 371-373.	0.8	2
107	Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT. Journal of Thoracic Disease, 2017, 9, E1148-E1150.	0.6	2
108	Impact of a Modified HistoGel Method for Processing Endocervical Curettage Specimens on Diagnostic Yield. American Journal of Clinical Pathology, 2021, 155, 141-147.	0.4	2

#	Article	IF	CITATIONS
109	Argon Plasma Coagulation (APC) for the Treatment of Excessive Dynamic Airway Collapse (EDAC). Journal of Bronchology and Interventional Pulmonology, 2021, 28, 221-227.	0.8	2
110	Critical values in cytology. Journal of the American Society of Cytopathology, 2021, 10, 341-348.	0.2	2
111	Pilot Gene Expression and Histopathologic Analysis of Tracheal Resections in Tracheobronchomalacia. Annals of Thoracic Surgery, 2022, 114, 1925-1932.	0.7	2
112	Suspicious for Malignancy. , 2018, , 101-118.		2
113	Pulmonary histopathology of interstitial lung disease associated with antisynthetase antibodies. Respiratory Medicine, 2022, 191, 106697.	1.3	2
114	Reply to: Endobronchial Optical Coherence Tomography: Shining New Light on Diagnosing UIP?. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	2
115	Adequacy of Pleural Fluid Cytology and Pleural Biopsies for Multiple Tumor Genotyping Techniques in Non-small Cell Lung Cancer. Chest, 2014, 146, 609A.	0.4	1
116	P1.02-031 Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes. Journal of Thoracic Oncology, 2017, 12, S506.	0.5	1
117	Repeat Contrast Medium Administration for Patients with Mild Immediate Hypersensitivity Reaction to lodinated Contrast Media. Radiology, 2019, 290, 270-271.	3.6	1
118	A Man with Superior Vena Cava Syndrome and Granulomas. Annals of the American Thoracic Society, 2020, 17, 107-111.	1.5	1
119	Atypical histologic presentation of Pneumocystis pneumonia as granulomatous lung nodules. Human Pathology: Case Reports, 2021, 23, 200476.	0.2	1
120	An Unusual Cause of Functional Mitral Stenosis. JACC: Case Reports, 2021, 3, 829-833.	0.3	1
121	A frameshift error affecting multiple cytology cell blocks: Lessons from a nearâ€miss event. Cancer Cytopathology, 2022, 130, 170-173.	1.4	1
122	The impact of pathology grossing protocol measures to improve pathologic nodal staging in lung cancer. Cancer Treatment and Research Communications, 2021, 29, 100488.	0.7	1
123	Pulmonary amyloidosis as the presenting finding in a patient with multiple myeloma. Respiratory Medicine Case Reports, 2022, 37, 101626.	0.2	1
124	Use of Lymph Node Aspirates From Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non-small Cell Lung Cancer. Chest, 2013, 144, 813A.	0.4	O
125	A 50-Year-Old Man with Cirrhosis and Progressive Hypoxemia. Annals of the American Thoracic Society, 2014, 11, 1149-1151.	1.5	O
126	Extended distance transmission over wideband MMF using multi-wavelength VCSEL based transceivers. , 2015, , .		O

#	Article	IF	CITATIONS
127	Pulmonary Cyst of Uterine Genesis. Chest, 2016, 150, 649A.	0.4	O
128	Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence. Clinical Lung Cancer, 2016, 17, e169-e172.	1.1	O
129	Thymic carcinoma with brain metastases: A rare presentation of a rare malignancy. Cancer Treatment Communications, 2016, 7, 21-22.	0.4	O
130	Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor–Resistant Setting. Journal of Thoracic Oncology, 2018, 13, e81-e83.	0.5	0
131	ENDOSCOPIC ARGON PLASMA COAGULATION FOR EXCESSIVE CENTRAL AIRWAY COLLAPSE: AN EXPERIMENTAL PILOT ANIMAL STUDY. Chest, 2019, 156, A202-A203.	0.4	O
132	False positive diagnosis of lymph node metastases in a 34â€yearâ€old woman with a history of extraskeletal myxoid chondroscarcoma: A root cause analysis. Cancer Cytopathology, 2019, 127, 69-71.	1.4	0
133	Molecular Diagnostics in Lung Cytology. , 2019, , 223-247.		O
134	A CASE OF FULMINANT CARDIAC SARCOIDOSIS RESEMBLING GIANT CELL MYOCARDITIS. Journal of the American College of Cardiology, 2020, 75, 2934.	1.2	0
135	Role of imaging in predicting tumor spread through airspaces (STAS): what are the next steps. Journal of Thoracic Disease, 2020, 12, 1154-1156.	0.6	O
136	Using the Model for Improvement and Planâ€Doâ€Studyâ€Act to effect SMART change and advance quality. Cancer Cytopathology, 2021, 129, 9-14.	1.4	0
137	A Case Report on Papillary Muscle Rupture Following Mitral Valve Replacement in the Setting of Previously Undiagnosed Amyloidosis. A& A Practice, 2021, 15, e01415.	0.2	O
138	Head and Neck: Thyroid. , 2014, , 123-159.		0
139	PD-1 antibody pembrolizumab administered at non-standard frequency in non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2019, 37, e20617-e20617.	0.8	O